Stock Track | CARsgen-B Soars 5.98% on Positive Topline Results from Phase II CAR-T Trial

Stock Track2024-12-31

CARsgen Therapeutics Holdings Ltd (02171), a leading biotech company, witnessed a significant surge of 5.98% in its stock price during the intraday trading session on Tuesday.

This rally can be attributed to the company's announcement of positive topline results from a pivotal Phase II clinical trial in China for its Claudin18.2 CAR-T cell therapy, SATRI-CEL. The study met its primary endpoint of improved progression-free survival (PFS), showcasing the therapy's potential efficacy in treating gastric cancer and gastroesophageal junction adenocarcinoma.

Encouraged by these promising results, CARsgen anticipates submitting a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China during the first half of 2025, paving the way for potential market approval and commercialization of SATRI-CEL.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145734059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-31 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145734059","market":"hk","top_or_hot":-1,"title":"Stock Track | CARsgen-B Soars 5.98% on Positive Topline Results from Phase II CAR-T Trial","media":"Stock Track","content":"<p>CARsgen Therapeutics Holdings Ltd (02171), a leading biotech company, witnessed a significant surge of 5.98% in its stock price during the intraday trading session on Tuesday.</p>\n\n<p>This rally can be attributed to the company's announcement of positive topline results from a pivotal Phase II clinical trial in China for its Claudin18.2 CAR-T cell therapy, SATRI-CEL. The study met its primary endpoint of improved progression-free survival (PFS), showcasing the therapy's potential efficacy in treating gastric cancer and gastroesophageal junction adenocarcinoma.</p>\n\n<p>Encouraged by these promising results, CARsgen anticipates submitting a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China during the first half of 2025, paving the way for potential market approval and commercialization of SATRI-CEL.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CARsgen-B Soars 5.98% on Positive Topline Results from Phase II CAR-T Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CARsgen-B Soars 5.98% on Positive Topline Results from Phase II CAR-T Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-31 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARsgen Therapeutics Holdings Ltd (02171), a leading biotech company, witnessed a significant surge of 5.98% in its stock price during the intraday trading session on Tuesday.</p>\n\n<p>This rally can be attributed to the company's announcement of positive topline results from a pivotal Phase II clinical trial in China for its Claudin18.2 CAR-T cell therapy, SATRI-CEL. The study met its primary endpoint of improved progression-free survival (PFS), showcasing the therapy's potential efficacy in treating gastric cancer and gastroesophageal junction adenocarcinoma.</p>\n\n<p>Encouraged by these promising results, CARsgen anticipates submitting a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China during the first half of 2025, paving the way for potential market approval and commercialization of SATRI-CEL.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1145734059","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145734059","pubTimestamp":1735609022,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CARsgen Therapeutics Holdings Ltd , a leading biotech company, witnessed a significant surge of 5.98% in its stock price during the intraday trading session on Tuesday.This rally can be attributed to the company's announcement of positive topline results from a pivotal Phase II clinical trial in China for its Claudin18.2 CAR-T cell therapy, SATRI-CEL. The study met its primary endpoint of improved progression-free survival , showcasing the therapy's potential efficacy in treating gastric cancer ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"II期CAR-T试验取得积极营收结果，股票赛道科济源-B飙升5.98%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARsgen Therapeutics Holdings Ltd (02171), a leading biotech company, witnessed a significant surge of 5.98% in its stock price during the intraday trading session on Tuesday.\nThis rally can be attributed to the company's announcement of positive topline results from a pivotal Phase II clinical trial in China for its Claudin18.2 CAR-T cell therapy, SATRI-CEL. The study met its primary endpoint of improved progression-free survival (PFS), showcasing the therapy's potential efficacy in treating gastric cancer and gastroesophageal junction adenocarcinoma.\nEncouraged by these promising results, CARsgen anticipates submitting a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China during the first half of 2025, paving the way for potential market approval and commercialization of SATRI-CEL.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145734059","isCrawlerRequest":true}